WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
I was the first person in the world to survive RABIES without a vaccine
Attorney says settlement being considered in NCAA antitrust case could withstand future challenges
Cubs place reliever Adbert Alzolay on injured list with right forearm strain and recall José Cuas
Brazil replaces injured goalkeeper Ederson in Copa America squad
Ukrainian schoolchildren head underground in bomb
Removal of remainder of Civil War governor's monument in North Carolina starting
French sports minister calls for sanctions after Monaco player tapes over anti
China auto association slams U.S. protectionism in NEV industry
Why US Catholics are planning pilgrimages in communities across the nation
Hedge fund operators go on trial after multibillion